ethyl 6-chloro-4-hydroxy-7-methoxyquinoline-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 6-chloro-4-hydroxy-7-methoxyquinoline-3-carboxylate
• 英文别名: ethyl 6-chloro-7-methoxy-4-oxo-1H-quinoline-3-carboxylate
• 化学式: C₁₃H₁₂ClNO₄
• 分子量: 281.696
• InChiKey: AAKUYWNSAMFENH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 6-chloro-4-hydroxy-7-methoxyquinoline-3-carboxylate 在 四(三苯基膦)钯 、 caesium carbonate 、 溶剂黄146 、 间氯过氧苯甲酸 、 三氯氧磷 、 三溴氧磷 作用下， 以 1,4-二氧六环 、 氯仿 、 水 为溶剂， 反应 10.0h， 生成 ethyl 2-(benzo[d][1,3]dioxol-5-yl)-6-chloro-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate
  参考文献：
  名称：

  Lead Optimization of 3-Carboxyl-4(1H)-Quinolones to Deliver Orally Bioavailable Antimalarials

  摘要：

  Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.

  DOI：

  10.1021/jm201642z
• 作为产物：
  描述：

  3-甲氧基-4-氯苯胺 以 二苯醚 、 乙醇 为溶剂， 反应 3.0h， 生成 ethyl 6-chloro-4-hydroxy-7-methoxyquinoline-3-carboxylate
  参考文献：
  名称：

  Lead Optimization of 3-Carboxyl-4(1H)-Quinolones to Deliver Orally Bioavailable Antimalarials

  摘要：

  Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.

  DOI：

  10.1021/jm201642z

文献信息

• [EN] COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1<br/>[FR] COMPOSÉS POUR LA DÉGRADATION DE BRD9 OU MTH1
  申请人：C4 THERAPEUTICS INC

  公开号：WO2020051235A1

  公开（公告）日：2020-03-12

  Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.

  提供了通过泛素蛋白酶体途径降解BRD9或MTH1的化合物，用于治疗需要的受体。提供的化合物具有与BRD9或MTH1的靶向配体相连的E3泛素连接酶靶向基团（Degron）。
• COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1
  申请人：C4 Therapeutics, Inc.

  公开号：EP3846800A1

  公开（公告）日：2021-07-14